IMPACT (0)

Investigation of Metformin effectiveness among Pre-diabetics on CVDs event reduction: A multi centric Clinical Trial
 

What Is IMPACT


This study is a multi-center, prospective, randomized, double-blind, parallel design trial comparing the effect of Metformin versus placebo on a macro vascular composite outcome and diabetes incidence in people in primary care with non-diabetic hyperglycemia (NDH) (100≤FPG<126) and at high cardiovascular risk (at least 10-year CVD risk ≥12% according to Framingham risk scoring/ QRISK2). Participants will be allocated randomly to be treated with either Metformin versus placebo plus life style modification if high risk for cardiovascular diseases, and will be followed for about 7 years. The purpose of clinical trial is to establish the effectiveness and cost effectiveness of Metformin in preventing cardiovascular events over seven years in people with non-diabetic hyperglycemia at high cardiovascular risk

 

 

Contact Info

  • Non-Communicable Diseases Research Center, Endocrinology and Metabolism Research Institute, Tehran University of Medical Sciences

    No. 10, Al-e-Ahmad and Chamran Highway intersection, Tehran

    Postcode: 1411713136

  • +9821-88631293
  • This email address is being protected from spambots. You need JavaScript enabled to view it.

Viewer's statistics

Today270
Yesterday384
This week654
This month8356
Total182358

Who Is Online

2
Online

Contact Us

ReCaptcha plugin is missing. Please install this plugin before!